arrow
I

Innocenzo Rainero

University of Turin
H指数:58
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness of rimegepant across multiple acute migraine attacks: A real-world, prospective, multicentric study

瑞美吉泮在多次急性偏头痛发作中的有效性:一项真实世界、前瞻性、多中心研究

2026-10-270
PRE
Exploring the links between amyloid, astrocytic activation, and tau biomarkers in a memory clinic cohort across the Alzheimer’s disease continuum

探索阿尔茨海默病连续谱系中记忆门诊队列中淀粉样蛋白、星形胶质细胞激活和tau生物标志物之间的关联

2026-09-240
OA
APOE-stratified genome-wide association analyses provide insights into the genetic etiology of Alzheimers’s disease

APOE分层的全基因组关联分析为阿尔茨海默病的遗传病因提供了见解

2026-09-140
OAAI
Building bridges in migraine management: consensus pathways on best practices across primary and specialist care in Italy

在偏头痛管理中构建桥梁:意大利初级保健和专科护理最佳实践的共识路径

2026-05-190
OAAI
Translation and validation of the Migraine Interictal Burden Scale (MIBS-4) in an Italian clinical cohort

偏头痛间期负担量表(MIBS-4)在意大利临床队列中的翻译与验证

2026-04-170
OAAI
The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability

阿托格匹兰特在偏头痛预防中的时辰药理学:关于给药时间对有效性和耐受性影响的真实世界评估

2026-03-250
PRE
Plasma pTau217/Aβ 42 and pTau217 outperform pTau181/Aβ 42 and pTau181 in predicting cerebrospinal fluid amyloid positivity: A real-world retrospective study

血浆pTau217/Aβ<sub>42</sub>和pTau217在预测脑脊液淀粉样蛋白阳性方面优于pTau181/Aβ<sub>42</sub>和pTau181:一项真实世界回顾性研究

2025-11-050
PRE
The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectiveness

意大利参与者在真实世界、泛欧洲、前瞻性、观察性、IV期PEARL研究中关于fremanezumab有效性的第二次中期分析

2025-10-170
OA
Hallmarks of primary headache: part 3 – cluster headache

原发性头痛的特征:第三部分——丛集性头痛

2025-10-030
OA
Machine learning in Alzheimer’s disease genetics

阿尔茨海默病遗传学中的机器学习

2025-07-220
OAAI
Transferability of European-derived Alzheimer’s disease polygenic risk scores across multiancestry populations

欧洲来源的阿尔茨海默病多基因风险评分在多祖先人群中的可转移性

2025-06-180
OA